German doctors cite knowledge gaps and regulatory barriers to prescribing…

[Why are German doctors reluctant to prescribe cannabis?].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen • • Highly Relevant
🤖

AI Summary

This study asked why doctors in Germany may be reluctant to prescribe medicinal cannabis. Researchers analyzed questionnaire responses from 153 volunteer physicians who attended occupational health training seminars; data were collected in 2018, 2020 and 2024. The survey assessed doctors’ knowledge, attitudes and prescribing practices, rather than testing cannabis as a treatment.

Doctors reported limited knowledge of medicinal cannabis, and as many as 70% did not answer some scenario-based knowledge questions correctly. Only 16.3% said they had prescribed medicinal cannabis. Respondents cited regulatory hurdles, including documentation demands and fear of legal consequences, as well as limited knowledge and concern about attracting drug users. Knowledge and attitudes did not show significant change over the survey years. Because participants were volunteers from training seminars, the findings may not represent all German doctors; this survey also cannot establish why prescribing levels are low across the country. This is an abstract-based summary.

💡 Key Findings

1
Among surveyed physicians, 16.3% reported having prescribed medicinal cannabis.
Good
70%
2
Knowledge was generally low; up to 70% of participants answered some clinical scenario questions incorrectly.
Good
70%
3
Doctors cited regulatory hurdles and structural concerns, including limited knowledge and fear of attracting drug users, as reasons for not prescribing.
Good
65%
4
The study found no significant change in knowledge or attitudes across the survey years.
Good
60%

📄 Original Abstract

BACKGROUND: Since cannabis flowers have been authorised as medicinal cannabis in Germany in 2017 and the requirement of a narcotics licence was lifted in 2024, both the quantities prescribed and the number of patients have fallen far short of initial expectations. The reasons for the marked reluctance among German doctors to prescribe cannabis products are varied and have not yet been systematically investigated. The primary aim of the study was to investigate doctors' knowledge, attitudes, and prescribing practices regarding medicinal cannabis in Germany. In particular, the study sought to identify the reasons for the reluctance to prescribe cannabis and to identify knowledge gaps and structural barriers. Secondary objectives related to the identification of factors associated with attitudes and prescribing practices, trends over time, as well as information and training needs. METHODS: Data were collected as part of a longitudinal study in 2018, 2020 and 2024 using a standardised questionnaire administered to doctors participating in an occupational health training seminar. A total of 166 questionnaires were distributed, of which 160 (96.4%) were returned; subsequently, 153 (75 women/78 men) questionnaires were analysed. The physicians, who took part on a voluntary basis, were 40 years old on average (ranging from 25 to 68 years). The questionnaire covered socio-demographic characteristics, general and medical knowledge, personal experience with cannabis, and the assessment of specific clinical scenarios. The significance level was set at 5%. RESULTS: Among the participants, 32.7% reported personal experiences with cannabis, whilst only 16.3% indicated that they had prescribed medicinal cannabis. Knowledge of medicinal, pharmacological, and legal aspects was generally low; in scenario-based knowledge questions, up to 70% of participants did not know the correct answer. Only 3.7% of participants were not interested in medicinal cannabis. The main reasons cited for not prescribing cannabis were regulatory hurdles (extensive documentation requirements, fear of legal recourse) and structural factors (lack of knowledge of indications and effects, concerns about attracting drug users). After applying the Bonferroni correction, there were only few significant differences between the subgroups; also, knowledge or attitudes towards medicinal cannabis did not change over the course of the survey years. DISCUSSION: German doctors demonstrate a high level of uncertainty regarding the use of medicinal cannabis, which is largely due to a lack of knowledge and, possibly, the long history of the criminalisation of cannabis by society. In order to promote evidence-based prescribing practices, independent, clinically oriented continuing professional development programmes on the indications and proven effects of medicinal cannabis are required.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.